Navigation Links
Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency
Date:1/12/2011

INDIANAPOLIS, Jan. 12, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee voted today to recommend non-approval of liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT), currently under FDA review for the treatment of exocrine pancreatic insufficiency (EPI).

During the meeting, the committee had questions about the degree of efficacy of liprotamase and recommended that additional studies be conducted prior to considering approval of liprotamase for EPI.  

"We appreciate the feedback the committee has provided, and we will continue to work with the FDA to address the questions raised in the meeting as the agency moves toward a final decision on the application," said Eiry Roberts, M.D., Vice President, Autoimmune, Bone-Muscle-Joint, Liprotamase Product Development at Lilly. "We remain confident in the clinical trial data package submitted to the FDA in support of the liprotamase application."

The FDA is not required to follow the recommendation of its advisory committees.

About Liprotamase & Pancreatic Enzyme Replacement Therapy

Liprotamase is an oral, non-porcine, pancreatic enzyme replacement therapy (PERT) under FDA review for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and pancreatectomy. PERT is a treatment involving the oral administration of pancreatic enzyme replacements, which include protease, amylase and lipase.

Patients with EPI cannot properly digest and absorb nutrients including fat, protein and carbohydrates. Causes of EPI include cystic fibrosis (a life-threatening genetic disorder), chronic pancreatitis and pancreatectomy (surgical removal of the pancreas).

Cystic fibrosis affects approximately 30,000 children and adults in the United States and nearly 100,000 people worldwide. Approximately 90 percent of cystic fibrosis patients receive PERT.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

This press release contains forward-looking statements about liprotamase for the treatment of exocrine pancreatic insufficiency (EPI). It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that liprotamase will be approved by the FDA on the anticipated timeline or at all, or that that it, will be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. The companies undertake no duty to update forward-looking statements.

P-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
2. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
3. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
4. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
5. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
6. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
7. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
8. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
9. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
10. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
11. VA Statement on Smoking Cessation Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 FinancialBuzz.com News ... According to ... was worth an estimated $6.6 billion in 2016, and is projected ... or reaching more than $24 billion by 2025. The medical cannabis ... growing from $4.7 billion in 2016, to an estimated $13.3 billion ...
(Date:3/22/2017)... 2017 EMD Serono, the biopharmaceutical business of Merck ... and Canada , today announced two new ... session at the 65 th Annual Pacific Coast Reproductive ... on March 24 th .   The results ... collected from July 2009 to December 2015 containing data from ...
(Date:3/22/2017)... MarketNewsUpdates.com News Commentary  ... As ... oil continues to rise in popularity with consumers, Cannabis ... enhancing production through acquiring innovative assets and other plant ... include: Future Farm Technologies Inc (OTC: FFRMF) (CSE: FFT.CN), mCig, ...
Breaking Medicine Technology:
(Date:3/22/2017)... CT (PRWEB) , ... March 22, 2017 , ... ... historic plan to cure Rett Syndrome, a devastating neurological disorder that afflicts 350,000 ... MECP2, located on the X chromosome, and almost exclusively strikes females. Following ...
(Date:3/22/2017)... ... 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, Heather Johnson and the ... in need of skilled pediatric dentistry in Rock Hill, SC, without a ... routine treatments, including cavities, sealants and fluoride applications, in a comfortable and fun environment. ...
(Date:3/22/2017)... York (PRWEB) , ... March 22, 2017 , ... ... Hospital have entered into a research collaboration to translate advances in basic neuroscience ... impairments at Blythedale and beyond. The collaboration seeks to improve movement, vision, and cognition ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... imaging core lab with extensive therapeutic experience and operational excellence in oncology clinical ... immuno-oncology clinical trial for the treatment of non-small cell lung cancer and small ...
(Date:3/22/2017)... ... March 22, 2017 , ... SNL Insurance ... to families and business owners in the greater Hampton Roads area, is embarking ... Society Relay For Life event. , Each year, hundreds of people living in ...
Breaking Medicine News(10 mins):